Utku
Nalan Utku, Dortmund DE
Patent application number | Description | Published |
---|---|---|
20080274910 | Method of Detecting Early Immune Activation - Provided are methods of diagnosing an early immune activation by detecting T-cell immune response cDNA 7 (TIRC7); in particular, TIRC7 as an early biomarker for the detection of transplant rejection in a non-invasive diagnostic methods is described that replaces biopsy intervention with a simple diagnostic method for monitoring after transplantation and furthermore, kits for uses in such methods of diagnosis are provided. | 11-06-2008 |
20140154279 | PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF TIRC7 - Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided. | 06-05-2014 |
Nalan Utku, Berlin DE
Patent application number | Description | Published |
---|---|---|
20110189181 | Use of agents derived from CEACAM1 for the treatment of inflammatory diseases - The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin is described. | 08-04-2011 |
20130323254 | THERAPEUTIC ANTI-TIRC7 ANTIBODIES FOR USE IN IMMUNE RELATED AND OTHER DISEASES - Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided. | 12-05-2013 |
Nalan Utku, Luxembourg LU
Patent application number | Description | Published |
---|---|---|
20140328841 | ANTI-CEACAM1 RECOMBINANT ANTIBODIES FOR CANCER THERAPY - Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer. | 11-06-2014 |
Nalân Utku, Bonn DE
Patent application number | Description | Published |
---|---|---|
20090175879 | NOVEL TARGET IN THE TREATMENT OF CYTOKINE RELEASE SYNDROME - A novel therapeutic and diagnostic target in the treatment of Cytokine Release Syndrome is provided. More specifically, a novel target is disclosed in the treatment of CRS occurring with diseases such as bacterial and viral infection as well as adverse reaction in drug therapy. | 07-09-2009 |
20130130998 | Analogues of Etoposide for the Treatment of Tumours - Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: | 05-23-2013 |
Nalân Utku, Bonn DE
Patent application number | Description | Published |
---|---|---|
20090175879 | NOVEL TARGET IN THE TREATMENT OF CYTOKINE RELEASE SYNDROME - A novel therapeutic and diagnostic target in the treatment of Cytokine Release Syndrome is provided. More specifically, a novel target is disclosed in the treatment of CRS occurring with diseases such as bacterial and viral infection as well as adverse reaction in drug therapy. | 07-09-2009 |
20120282272 | NOVEL TARGET IN THE TREATMENT OF CYTOKINE RELEASE SYNDROME - A novel therapeutic and diagnostic target in the treatment of Cytokine Release Syndrome is provided. More specifically, a novel target is disclosed in the treatment of CRS occurring with diseases such as bacterial and viral infection. as well as adverse reaction in drug therapy. | 11-08-2012 |
Nalân Utku, Dortmund DE
Patent application number | Description | Published |
---|---|---|
20110183921 | PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF TIRC7 - Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided. | 07-28-2011 |